Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Visual Rehabilitation After Occipital Stroke

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04798924
Recruitment Status : Recruiting
First Posted : March 15, 2021
Last Update Posted : October 20, 2021
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Krystel Huxlin, University of Rochester

Brief Summary:
This research aims to examine changes in plastic potential of the visual system with time from stroke affecting primary visual cortex. We will measure structural and mechanistic aspects of progressive degeneration along the early visual pathways, correlating them with changes in visual performance, and in responsiveness to visual restoration training. This project will advance both scientific knowledge, as well as technical capability and clinical practices for restoring vision and quality of life for people suffering from cortical blindness.

Condition or disease Intervention/treatment Phase
Stroke, Ischemic Hemianopsia, Homonymous Hemianopia Quadrantanopia Vision Loss Partial Device: Subacute Training in the intact field Device: Subacute Training in the blind field Device: Chronic Training in the blind field Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Visual Rehabilitation After Occipital Stroke
Actual Study Start Date : July 19, 2021
Estimated Primary Completion Date : March 15, 2024
Estimated Study Completion Date : March 15, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rehabilitation

Arm Intervention/treatment
Experimental: Training in the blind field
Training in the blind field using specialized software
Device: Subacute Training in the blind field
A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.

Device: Chronic Training in the blind field
After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.

Experimental: Training in the intact field
Training in the intact field using specialized software
Device: Subacute Training in the intact field
A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the intact field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.

Device: Chronic Training in the blind field
After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.




Primary Outcome Measures :
  1. Direction Discrimination Threshold [ Time Frame: baseline, 6 months, 12 months ]

    For each subject, we will measure the ability to detect differences in the motion direction of visual stimuli relative to horizontal, measured in degrees of visual angle. These assessments will be based on what can be reliably detected at a 72-75% correct level of performance.

    These measures of change will be evaluated baseline to 6-months post-stroke, then 6- to 12-months post stroke, and baseline to 12-months.**

    **NOTE: Our protocol allows for a +1 month variance for all timepoints.



Secondary Outcome Measures :
  1. Direction Integration Threshold [ Time Frame: baseline, 6 months, 12 months ]

    This will measure the ability of subjects to integrate across a range of motion directions measured in degrees of visual angle. These assessments will be based on what range of motion directions can be reliably integrated at a 72-75% correct level of performance.

    These measures of change will be evaluated baseline to 6-months post-stroke, then 6- to 12-months post stroke, and baseline to 12-months.

    **NOTE: Our protocol allows for a +1 month variance for all timepoints.


  2. Contrast Sensitivity for Direction [ Time Frame: baseline, 6 months, 12 months ]

    Assessment of visual perception transfer to untrained psychophysical tasks of contrast sensitivity for direction discrimination.

    For each subject, we will measure the ability to correctly detect the motion direction of visual stimuli that are also varying in contrast against a grey background. We will measure the luminance contrast that can be reliably detected at a 72-75% correct level of performance.

    These measures of change will be evaluated baseline to 6-months post-stroke, then 6- to 12-months post stroke, and baseline to 12-months.

    **NOTE: Our protocol allows for a +1 month variance for all timepoints.


  3. contrast sensitivity for static orientation [ Time Frame: baseline, 6 months, 12 months ]

    Assessment of visual perception transfer to untrained psychophysical tasks of contrast sensitivity for static orientation discrimination.

    For each subject, we will measure the ability to correctly detect the orientation of non-moving visual stimuli that vary in contrast against a grey background. We will measure the luminance that can be reliably detected at a 72-75% correct level of performance.

    These measures of change will be evaluated baseline to 6-months post-stroke, then 6- to 12-months post stroke, and baseline to 12-months.

    **NOTE: Our protocol allows for a +1 month variance for all timepoints.


  4. Ganglion cell complex thickness laterality [ Time Frame: baseline, 6 months, 12 months ]

    Change in thickness of the ganglion cell complex will be measured by retinal optical coherence tomography (OCT) scans from baseline to 6- and 12- months post stroke.**

    We will perform OCT imaging of the foveal region of the retina (6mm ETDRS) in both eyes of each patient. Images will be automatically segmented. Estimated thickness of the ganglion cell complex will be extracted and aligned with estimates of the blind field's visual sensitivity obtained from fundus-controlled MAIA perimetry. We will then compute a laterality index LI as follows: LIGCCT=(Tc-Ti)/(Tc+Ti) where Tc=thickness in the control lateral OCT quadrant, Ti=thickness in the impaired lateral OCT quadrant.

    **NOTE: Our protocol allows for a +1 month variance for all timepoints.


  5. Ganglion cell complex volume laterality [ Time Frame: baseline, 6 months, 12 months ]

    Change in volume of the ganglion cell complex will be measured by retinal optical coherence tomography (OCT) scans from baseline to 6- and 12- months post stroke.**

    We will perform OCT imaging of the foveal region of the retina (6mm ETDRS) in both eyes of each patient. Images will be automatically segmented. Estimated volume of the ganglion cell complex will be extracted and aligned with estimates of the blind field's visual sensitivity obtained from fundus-controlled MAIA perimetry. We will then compute a laterality index as follows: LIGCCT=(Tc-Ti)/(Tc+Ti) where Tc=thickness in the control lateral OCT quadrant, Ti=thickness in the impaired lateral OCT quadrant.

    **NOTE: Our protocol allows for a +1 month variance for all timepoints.


  6. Optic Tract (OT) laterality [ Time Frame: baseline, 6 months, 12 months ]
    OT volume analysis will be performed from high resolution structural T1 MRI images of the brain. Mirrored masks of equal size will be hand-drawn over the OTs in each brain slice of a given subject, starting three slices posterior to the optic chiasm and continuing posteriorly until the OTs are no longer distinct from surrounding structures. The volume of each optic tract will be calculated from these masks by first establishing the maximum voxel intensity (range from 0 to 255) across the two OTs, then counting the number of voxels in each OT mask with brightness values between 5 and 85% of this maximum. We will then compute an OT laterality Index (LI85) to represent the relative difference in estimated volume between the two OTs of each participant, where LI85=(OTc-OTi)/(OTc+OTi), where OTc=number of voxels with brightness 5-85% of maximum in the contralesional OT and OTi = number of voxels with brightness 5-85% of maximum in the ipsilesional OT.


Other Outcome Measures:
  1. MAIA Visual Field Perimetry [ Time Frame: baseline, 6 months, 12 months ]

    We will measure the change in visual sensitivity (measured in decibels) at all locations tested by the system. These changes will be measured and compared between baseline, 6-months post stroke, and 12 months post stroke.**

    **NOTE: Our protocol allows for a +1 month variance for all timepoints.


  2. Humphrey 10-2 and 24-2 perimetry [ Time Frame: baseline, 6 months, 12 months ]

    We will measure the change in visual sensitivity (measured in decibels) at all locations tested by the system. These changes will be measured and compared between baseline, 6-months post stroke, and 12 months post stroke.**

    **NOTE: Our protocol allows for a +1 month variance for all timepoints.


  3. Goldmann perimetry [ Time Frame: baseline, 6 months, 12 months ]

    We will measure the change in area of vision (degrees squared) as encompassed by each isopter, measured by one of 3 different light stimuli.

    The 3 isopters we will compare are:

    1. I2e 1asb, 0.25 mm^2
    2. I4e 10asb, 0.25 mm^2
    3. V4e 1000asb, 64 mm^2

    These changes will be measured and compared between baseline, 6-months post stroke, and 12 months post stroke.**

    **NOTE: Our protocol allows for a +1 month variance for all timepoints.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Residents of US and Canada
  • MRI and/or CT scans showing evidence of stroke or stroke-like damage to the primary visual cortex or its immediate afferent white matter sustained less than 6-months prior to enrollment
  • Reliable visual field defects in both eyes as measured by Humphrey, Macular Integrity Assessment (MAIA), Goldmann, and/or equivalent perimetry. This deficit must be large enough to enclose a 5-deg diameter visual stimulus.
  • Ability to fixate on visual targets reliably for 1000ms (as demonstrated by visual fields, and verified in study participation)
  • Willing and safely able to undergo magnetic resonance imaging (MRI) scanning
  • Willing, able, and competent to provide informed consent
  • Fluent in written and spoken English
  • Cognitively able, responsible, and willing to complete daily visual training independently at home for several months.

Exclusion Criteria:

  • Past or present ocular disease interfering with vision
  • Best corrected visual acuity worse than 20/40 in either eye
  • Presence of damage to the dorsal Lateral Geniculate Nucleus, as shown on MRI/CT scans
  • Diffuse, whole brain degenerative processes
  • Brain damage deemed by study staff to potentially interfere with training ability or outcome measures
  • History of traumatic brain injury
  • Documented history of drug/alcohol abuse
  • Currently use of neuroactive medications which would impact training, as determined by PI
  • Cognitive or seizure disorders
  • One-sided attentional neglect
  • Inability to perform the visual training exercises as directed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04798924


Contacts
Layout table for location contacts
Contact: Chrys Callan 585-276-3426 Christine_Callan@URMC.Rochester.Edu

Locations
Layout table for location information
United States, New York
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Christine Callan    585-276-3426    christine_callan@urmc.rochester.edu   
Principal Investigator: Krystel Huxlin, PhD         
Sponsors and Collaborators
University of Rochester
National Institutes of Health (NIH)
Layout table for additonal information
Responsible Party: Krystel Huxlin, James V. Aquavella Professor of Ophthalmology, Associate Chair for Research, Dept. Ophthalmology, University of Rochester
ClinicalTrials.gov Identifier: NCT04798924    
Other Study ID Numbers: 00005966
First Posted: March 15, 2021    Key Record Dates
Last Update Posted: October 20, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Krystel Huxlin, University of Rochester:
stroke induced vision loss
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Ischemic Stroke
Hemianopsia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Blindness
Eye Diseases